Skip to main content
NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · Real-Time Price · USD
26.28
+0.52 (2.02%)
Aug 14, 2025, 7:17 AM - Market open

NAMS Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
 TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
 Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Revenue
64.0145.5614.09102.69--
Revenue Growth (YoY)
762.15%223.37%-86.28%---
Gross Profit
64.0145.5614.09102.69--
Selling, General & Admin
93.9370.4537.6319.5161.69
Research & Development
142.86151.41159.4286.7428.974.95
Operating Expenses
236.8221.85197.06106.2534.986.64
Operating Income
-172.79-176.29-182.97-3.56-34.98-6.64
Interest Expense
----0.29-0.41-0.42
Interest & Investment Income
23.3316.8811.28---
Currency Exchange Gain (Loss)
9.73-6.65.06-9.751.710.03
Other Non Operating Income (Expenses)
1.42-38.58-10.02-8.34-7.22-
EBT Excluding Unusual Items
-138.3-204.59-176.64-21.93-40.9-7.03
Other Unusual Items
-27.41-37.01-0.27-0.71-0.88-
Pretax Income
-165.72-241.6-176.91-22.63-41.79-7.03
Income Tax Expense
-0-00.03---
Net Income
-165.72-241.6-176.94-22.63-41.79-7.03
Net Income to Common
-165.72-241.6-176.94-22.63-41.79-7.03
Shares Outstanding (Basic)
107948219115
Shares Outstanding (Diluted)
107948219115
Shares Change (YoY)
23.19%14.84%333.20%72.75%119.58%-
EPS (Basic)
-1.55-2.56-2.15-1.19-3.81-1.41
EPS (Diluted)
-1.55-2.56-2.15-1.19-3.81-1.41
Free Cash Flow
-124.3-159.24-141.2410.44-29.54-7.32
Free Cash Flow Per Share
-1.16-1.69-1.720.55-2.69-1.46
Gross Margin
100.00%100.00%100.00%100.00%--
Operating Margin
-269.96%-386.91%-1298.56%-3.46%--
Profit Margin
-258.90%-530.25%-1255.76%-22.04%--
Free Cash Flow Margin
-194.21%-349.49%-1002.43%10.17%--
EBITDA
-172.62-176.18-182.92-3.55-34.97-6.64
EBITDA Margin
-269.69%---3.45%--
D&A For EBITDA
0.180.110.050.010.010
EBIT
-172.79-176.29-182.97-3.56-34.98-6.64
EBIT Margin
-269.96%---3.46%--
Updated Feb 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q